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Abstract
Graves’ orbitopathy (GO) is characterised in early stages by orbital fibroblast inflammation,
which can be aggravated by oxidative stress and often leads to fibrosis. Protein tyrosine
protein 1B (PTP1B) is a regulator of inflammation and a therapeutic target in diabetes. We
investigated the role of PTP1B in the GO mechanism using orbital fibroblasts from GO and
healthy non-GO subjects. After 24 hours of transfection with PTPN1 siRNA, the fibroblasts
were exposed to interleukin (IL)-1β, cigarette smoke extract (CSE), H2O2, and transforming
growth factor (TGF)-β stimulations. Inflammatory cytokines and fibrosis-related proteins
were analysed using western blotting and/or enzyme-linked immunosorbent assay (ELISA).
Reactive oxygen species (ROS) release was detected using an oxidant-sensitive fluores-
cent probe. IL-1β, tumor necrosis factor (TNF)-α, bovine thyroid stimulating hormone
(bTSH), high-affinity human stimulatory monoclonal antibody of TSH receptor (M22), and
insulin-like growth factor-1 (IGF-1) significantly increased PTP1B protein production in GO
and non-GO fibroblasts. PTPN1 silencing significantly blocked IL-1β-induced inflammatory
cytokine production, CSE- and H2O2-induced ROS synthesis, and TGF-β-induced expres-
sion of collagen Iα, α-smooth muscle actin (SMA), and fibronectin in GO fibroblasts. Silenc-
ing PTPN1 also decreased phosphorylation levels of Akt, p38, and c-Jun N-terminal kinase
(JNK) and endoplasmic reticulum (ER)-stress response proteins in GO cells. PTP1B may
be a potential therapeutic target of anti-inflammatory, anti-oxidant and anti-fibrotic treatment
of GO.
Introduction
Graves’ orbitopathy (GO) is an orbital involvement of autoimmune thyroid disease; it occurs
in approximately 50% of Grave’s disease and 2% of chronic thyroiditis [1, 2]. Clinical manifes-
tations include lid swelling, lid retraction, proptosis, and ocular movement limitations;
3–5% of patients have a severe form, including pain, inflammation, and compressive optic
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neuropathy [1–3]. Orbital fibroblasts dysregulated by autoantibodies to thyrotropin receptor
and IGF-1 receptor (IGF-1R) play a key role in the pathogenesis of GO. Furthermore, orbital
fibroblasts differentiate into adipocytes, accumulating fatty tissue and producing hyaluronan,
which leads to the typical findings of GO [3, 4]. Mononuclear cells, such as macrophages, T
cells, and B cells, infiltrating the orbital tissue orchestrate the pathogenic inflammatory pro-
cesses; moreover, ROS have been found to aggravate GO [5]. As inflammation in the orbital
tissue is the primary aetiology of GO, glucocorticoids have been used as first-line treatment;
however, their systemic complications have prompted researchers to explore alternative treat-
ment options.
Protein tyrosine phosphatase 1B (PTP1B), encoded by the PTPN1 gene, is a ubiquitously
expressed non-receptor protein tyrosine phosphatase enzyme that dephosphorylates tyrosine-
phosphorylated proteins. It is expressed in multiple tissues, including the skeletal muscle, liver,
adipose tissue, and brain [6]. PTP1B is a negative regulator of the leptin and insulin signalling
pathways. It has been investigated as a therapeutic agent in diabetes and obesity following
observations that mice with whole-body deletion of PTP1B exhibited increased insulin sensi-
tivity and reduced weight gain when reared on a high-fat diet [7, 8]. PTP1B is also known to be
involved in immune cell signalling [9, 10] by regulating cytokines via dephosphorylation of
janus kinase (JAK)2, signal transducer and activator of transcription (STAT)5, and tyrosine
kinase (TYK)2 [11, 12]. However, depending on the cell or tissue type, PTP1B displays differ-
ent specific roles; for example, PTP1B knockout (KO) induced no change in inflammation in
neuronal cells but resulted in upregulation of inflammation in B cells [13].
As the role of PTP1B in GO has not yet been studied, we characterised the effect of PTP1B
in Graves’ orbital fibroblasts in response to proinflammatory and oxidative stress challenges,
which simulate the main pathogenesis of GO.
Materials and methods
Reagents and chemicals
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin, and gen-
tamycin were purchased from Hyclone Laboratories, Inc. (Logan, UT, USA). Recombinant
human IL-1β, TNF-α and IGF-1 were purchased from R&D Systems (Minneapolis, UT, USA).
M22 was purchased from RSR Ltd. (Llanishen, Cardiff, UK) and bTSH was obtained from
Genzyme Corporation (Cambridge, MA, USA). TGF-β and antibodies for PTP1B, phosphory-
lated (p)-Akt, total (t)-Akt, p-extracellular signal-related kinase (ERK), t-ERK, p-p38, t-p38, p-
JNK, t-JNK, cyclooxygenase (Cox)-2, intercellular adhesion molecule (ICAM)-1, p-nuclear
factor (NF)-κB, t-NF-κB, binding immunoglobulin protein (BiP), p-eukaryotic translation
initiation factor (eIF)2α, t-eIF2α, p-inositol-requiring enzyme (IRE)1α, t-IRE1α, p-protein
kinase R-like endoplasmic reticulum kinase (PERK), t-PERK, activating transcription factor
(ATF)4, ATF6α, and C/EBP-homologous protein (CHOP) were obtained from Cell Signaling
Technology (Beverly, MA, USA), the antibody for fibronectin was obtained from BD Biosci-
ence (Franklin Lake, NJ, USA), and the α-SMA antibody was obtained from Sigma-Aldrich
(Saint Louis, MO, USA). collagen Iα, and anti–β-actin antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Tissue and cell preparation
Orbital adipose tissues were harvested from surgical by-products during orbital decompres-
sion surgery in 4 patients with GO (3 males, 1 female; age 37–55 years). At the time of the sur-
gery, patients were in a stable euthyroid state and their clinical activity scores (CAS) were 3 or
less. Normal control adipose tissues were obtained from 3 patients with no history of GO (1
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male, 2 females; age 36–52 years) during lid blepharoplasty (Table 1). All patients provided
written informed consent. This study was approved by the institutional review board of Sever-
ance Hospital, Yonsei University College of Medicine (Seoul, Korea) and followed the tenets
of the Declaration of Helsinki.
Orbital fibroblasts were cultured according to the method used in our previous study
[14]. Briefly, the tissue was minced and placed in DMEM:F12 (1:1) containing 20% FBS, pen-
icillin (100 U/mL), and gentamicin (20 μg/mL). Following fibroblast growth, the cells were
passaged serially treating them with trypsin/ethylenediaminetetraacetic acid (EDTA). Strains
were stored in liquid nitrogen. Only strains between the 3rd and 6th passages were used for
experiments.
Silencing of PTP1B
Small interfering RNA (siRNA) designed to silence the PTP1B gene (PTPN1) and negative
control #1 siRNA were purchased from Ambion/Applied Biosystems (s11507; Ambion, Aus-
tin, Texas, USA). Transfection was performed with Lipofectamine RNAiMAX (Invitrogen)
according to the instructions of the supplier. Cells (1 × 105 cells/well) were supplemented with
10% FBS and antibiotics and maintained for a 24-hour period.
Western blot
Orbital fibroblasts treated with each reagent were washed with phosphate-buffered saline
(PBS) and lysed in cell lysis buffer on ice in accordance with the methods described in our pre-
vious study [14]. Cell lysates were centrifuged to produce homogenous cell fractions, which
were then boiled in buffer. Proteins were resolved by 10% SDS-PAGE, transferred to polyviny-
lidene fluoride membranes (Immobilon; Millipore Corp., Billerica, MA, USA), and treated
with primary antibodies overnight in Tris-buffered saline and Tween 20 (TBST). Immunore-
active bands were detected with horseradish peroxidase and its secondary antibody. The
bound peroxidase was visualised by chemiluminescence (Amersham Pharmacia Biotech, Inc.,
Piscataway, NJ, USA) and exposure to X-ray film (Amersham Pharmacia Biotech, Inc.). Pro-
tein was quantified via densitometry and normalised to the level of β-actin in each sample.
Enzyme-linked immunosorbent assay
To quantify the levels of IL-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1), superna-
tants collected from cell culture were evaluated using an ELISA kit (R&D system, Minneapolis,
Table 1. Clinical information of patient samples used in this in vitro study.
Age (years) Sex CAS Smoker Duration of GO (years) Proptosis R/L (mm) Surgery performed
GO patients
37 F 3/7 N 2.0 21/21 Decompression
42 M 1/7 Y 2.1 21/21 Decompression
52 M 0/7 N 4.2 21/20 Decompression
55 M 1/7 N 3.0 23/23 Decompression
Non-GO control subjects
52 F n/a N n/a n/a Lower lid blepharoplasty
36 M n/a N n/a n/a Upper lid blepharoplasty
51 F n/a N n/a n/a Upper lid blepharoplasty
Abbreviations: GO, Graves’ orbitopathy; CAS, clinical activity scores; Y, yes; N, No; n/a; not applicable; F, female; M, male; R, right eye; L, left eye.
https://doi.org/10.1371/journal.pone.0237015.t001
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UT, USA) according to the manufacturer’s protocol. Absorbance of the samples was measured
at 450 nm using microplate reader (Molecular Devices, Sunnyvale, CA, USA) and the percent-
age of binding was calculated.
Real-time PCR
RNA was extracted from orbital tissues, which were homogenized with a tissue homogenizer
(Precellys1 24; Bertin Instruments, Montigny-le-Bretonneux, France) using a Precellys lysing
kit (Bertin Instruments) with TriZol (Invitrogen, Carlsbad, CA, USA) and cDNA was synthe-
sized. PCR was performed using TaqMan universal PCR master mix in an ABI 7300 real-time
PCR thermocycler (Applied Biosystems, Carlsbad, CA, USA). Primers for Toll-like receptor
(TLR) 2, 4, and 9 were as follows: TLR2; 5’-GAC TTC TCC CAT TTC CGT CT-3’ (for-
ward), 5’-CAG GTA GGT CTT GGT GTT CA-3’ (reverse), TLR4; 5’-GAC CTT TCC
AGC AAC AAG ATT C-3’ (forward), 5’-GAG AGA TTG AGT AGG GGC ATT T-3’
(reverse), TLR9; 5’-GGC TGG TAT AAA AAT CTT ACT TCC TC-3’ (forward), 5’-
CAC ACT CGA GGT CCC TTC C-3’ (reverse); these primers were designed using Applied
Biosystems software and GAPDH were No. Hs99999905_m1. The results were expressed
using the 2−ΔΔCt method, as relative exponential changes of threshold cycle (Ct) relative to
the control group. The amplified band was quantified through densitometry and normalized
against GAPDH. RT-PCR was performed in duplicate in three cells from different individuals.
Intracellular ROS measurement
CSE and H2O2 were used to induce ROS production as previously reported [15]. CSE was pre-
pared from two commercially available cigarettes containing 8.0 mg tar and 0.7 mg nicotine
(Marlboro 20 class A; Philip Morris Korea, Inc., Seoul, Korea) as described previously [15].
Here, 2% CSE and 200 μM H2O2 were used to generate oxidative stress in cells without reduc-
ing cell viability. Cells (1 × 105 cells/well) were exposed to oxidative stressors, washed with
PBS, and incubated with the oxidant-sensitive fluorescent probe 5-(and 6)-carboxy-2’,7’-
dichloro-dihydrofluorescein diacetate (H2DCFDA; Invitrogen, Eugene, OR, USA) for 30 min-
utes. The cells were then trypsinised, washed, and resuspended in PBS. To measure fluores-
cence intensity, a flow cytometer (ELITE flow cytometer; Coulter Cytometry, Inc., Hialeah,
FL, USA) was used, and fluorescent photos were taken using an IX71-F22PH inverted fluores-
cence microscope (Olympus Corp., Tokyo, Japan).
Cell viability and apoptosis assays
Cell viability after PTPN1 blockade was evaluated with a 3-(4, 5-dimethyl thiazol-2-yl)-2,
5-diphenyl tetrazolium bromide (MTT) assay. Orbital fibroblasts from GO and non-GO
patients with sicontrol or siPTPN1 transfection were seeded in 24-well culture plates (1 × 105
cells/well) and were treated with IL-1β (10 ng/mL) for 24 and 48 hours. After treatment, cells
were washed and incubated with 5 mg/mL MTT solution for 3 hours at 37 ˚C and then stabi-
lized in ice-cold isopropanol. Microplate reader (EL 340 Bio Kinetics Reader; Bio-Tek Instru-
ments, Winooski, VT, USA) was used to measure the absorbance of the dye at 490 nm.
An annexing V-FITC kit (R&D systems, Minneapolis, MN, USA) was used to assess apo-
ptotic cells with PTPN1 blockade. Cells were washed with PBS and incubated with annexin V
labeled with FITC and propidium iodide (PI) for 15 minutes at room temperature. Apoptotic
cells were analyzed using a fluorescence-activated cell sorter (FACS, Becton Dickinson-FACS-
calibur, Cockeysville, MD, USA). In total, 10,000 cells were excited at 488 nm and emission
was measured at 515–545 nm and 600 nm to assess FITC and PI, respectively.
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Statistical analysis
IBM SPSS Statistics for Windows v 20.0 (IBM Corp., Armonk, NY) was used for statistical
analyses. All experiments were performed in duplicate on three samples from different indi-
viduals, and the results are expressed as the mean values ± standard deviation. The Mann–
Whitney U-test and Kruskal–Wallis test were used for nonparametric data, and the Kolmogo-
rov–Smirnov test was used for data that was not normally distributed. A p-value less than 0.05
was considered statistically significant.
Results
TSH and IGF-1 increased PTP1B production in orbital fibroblasts
Fibroblasts were stimulated with IL-1β (10 ng/mL) or TNF-α (10 ng/mL) for 48 hours to eval-
uate PTP1B expression changes in response to inflammatory stimulation in GO and non-GO
cells, as previously reported [14, 16, 17]. We also treated cultures with IGF-1 (100 ng/mL),
M22 (10 ng/mL), or bTSH (2.5 mU/mL). PTP1B protein production was increased signifi-
cantly by all these stimulants in both GO and non-GO cells (p<0.05) (Fig 1).
PTP1B inhibition reduces IL-1β-induced inflammation in GO orbital
fibroblasts
To clarify the role of PTP1B in inflammatory stimulation, PTPN1 was silenced via transfection
of PTPN1-targeting siRNA (siPTPN1); silencing efficiency of siPTPN1 compared with sicon-
trol (sicon in figures) was verified using western blot. We then treated PTPN1-silenced GO
and non-GO cells with IL-1β (10 ng/mL) for 48 hours and measured the production of pro-
inflammatory cytokines, IL-6, IL-8 and MCP-1 using ELISA. GO cells secreted more proteins
of IL-6, IL-8 and MCP-1 than non-GO cells under basal and IL-1β stimulated condition.
Down-regulation of PTP1B by siPTPN1 inhibited the secretion of IL-6, IL-8, and MCP-1
Fig 1. PTP1B protein expression stimulated by proinflammatory cytokines, TSH Receptor (TSHR), and IGF-1R ligands. Orbital fibroblasts
cultured from GO and non-GO tissues were treated with IL-1β (10 ng/mL), TNF-α (10 ng/mL), M22 (10 ng/mL), bTSH (2.5 mU/mL), or IGF-1 (100
ng/mL) for 48 hours. Cell lysates were subjected to western blot. IL-1β, TNF-α, M22, bTSH, and IGF-1 significantly increased the expression of PTP1B
protein in both GO and non-GO fibroblasts. Experiments were performed in three GO and non-GO cells from different individuals. Data in the
columns indicate the mean density ratio ± SD by densitometry normalised to the level of β-actin in the same sample. Representative gel images are
shown. Differences between treated and untreated cells are indicated (�p<0.05). See S3 Fig for uncropped blots.
https://doi.org/10.1371/journal.pone.0237015.g001
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in GO cells with or without IL-1β (�p<0.05), but not in non-GO cells (Fig 2A and 2B). In
western blot analyses, IL-1β-induced Cox-2 and ICAM-1 protein production was reduced in
siPTPN1-treated GO cells and only Cox-2 expression was attenuated in siPTPN1-treated non-
GO cells (Fig 2C). Stimulation of fibroblasts with IL-1β (10 ng/mL) for 1 hour increased the
p-NF-κB production; however, this upregulation was suppressed by PTPN1 silencing in GO
cells.
TLRs participate in autoimmune diseases [18] and TLR-related signaling activates NF-κB
to secrete inflammatory cytokines [19]. After transfection of GO and non-GO fibroblasts
with siPTPN1 for 24 hours, TLR2, 4, and 9 mRNA expression levels were identified through
RT-PCR analysis. TLR2, 4, and 9 were suppressed through PTPN1 inhibition in GO fibro-
blasts. In non-GO fibroblasts, TLR4 and 9 were suppressed through PTPN1 inhibition
(�p<0.05) (S1 Fig).
PTP1B inhibition reduces ROS generation upon CSE and H2O2
stimulation
GO orbital fibroblasts were treated with 2% CSE or 200 μM H2O2 for 30 minutes. In PTPN1-
silenced GO cells, CSE- or H2O2-induced intracellular ROS generation was reduced signifi-
cantly as detected by H2DCFDA (
�p<0.05) (Fig 3A and 3B).
PTP1B suppression results in an anti-fibrotic effect
We also investigated whether PTP1B suppression has an effect on the expression of fibrosis-
related proteins. Fibronectin, collagen Iα, and α-SMA protein expression was evaluated after
24 hours of TGF-β (5 ng/mL) stimulation in sicontrol cells and siPTPN1 cells. Enhanced
expression of fibronectin, collagen Iα, and α-SMA following TGF-β treatment was signifi-
cantly inhibited in the siPTPN1-transfected GO cells (�p<0.05) (Fig 4A). In non-GO cells,
only collagen Iα was inhibited after PTPN1 blocking (�p<0.05) (Fig 4B).
Role of PTP1B suppression in ER stress
PTP1B is a negative regulator of insulin signalling and is localised on the ER membrane. ER
stress was induced in GO cells by treatment with IL-1β (10 ng/mL) for 1 hour and 48 hours.
Silencing of PTPN1 with siRNA significantly suppressed the protein expression of BiP, p-
IRE1α, and CHOP induced by 1 hour IL-1β treatment as well as the protein expression of BiP,
p-eIF2α, p-IRE1α, ATF4, and CHOP induced by 48 hours of IL-1β treatment in GO cells
(�p<0.05). The expression levels of PERK and ATF6α were not changed by silencing of
PTPN1 (Fig 5).
We investigated the effect of PTPN1 silencing on cell viability and apoptosis whether the
suppression of ER stress protein by PTP1B suppression was associated with apoptosis [20, 21].
Upon IL-1β stimulation for 48 hours, GO fibroblasts displayed increased proliferative activity
(�p<0.05). Treatment with IL-1β for 24 hours and 48 hours in both sicontrol and siPTPN1-
transfected cells did not change cell viability in both GO and non-GO fibroblasts (S2A Fig).
The sicontrol and siPTPN1-transfected cells were subjected to an Annexin V apoptosis assay
after incubation for 24 and 48 hours. PTPN1 inhibition did not significantly increase apoptosis
or necrosis in GO and non-GO fibroblasts (S2B Fig).
Effect of PTP1B suppression on signal pathway molecules
The phosphoinosidie 3-kinase (PI3K)-Akt pathway has been reported to be involved in GO
[22, 23] and mitogen-activated protein kinase (MAPK) is well-known for its involvement in
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Fig 2. Effect of PTP1B suppression on proinflammatory cytokine production. After transfection of GO and non-GO fibroblasts with
siPTPN1 for 24 hours, cells were treated with IL-1β (10 ng/mL) for 1 hour or 48 hours for the evaluation of NF-κB or inflammatory cytokine
production, respectively. Experiments were performed in three GO and non-GO cells from different individuals. In sicontrol cells and
siPTPN1 cells, IL-6, IL-8, and MCP-1 protein release was analysed under basal condition (A) and after 48 hours of IL-1β (10 ng/mL)
stimulation (B) using ELISA (�p<0.05, sicontrol versus siPTPN1 cells). (C) Protein expression levels of ICAM-1, Cox-2, and p-NF-κB in
sicontrol and siPTPN1 cells with or without IL-1β (10 ng/mL) stimulation were evaluated using western blot analysis. Representative bands
are shown. See S3 Fig for uncropped blots.
https://doi.org/10.1371/journal.pone.0237015.g002
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inflammatory diseases [24, 25]. After treatment of sicontrol fibroblasts with IL-1β (10 ng/mL)
for 1 hour, Akt, ERK, p38, and JNK phosphorylation increased significantly in both GO and
non-GO cells. However, when PTP1B was suppressed by siPTPN1 transfection, Akt, p38, and
JNK phosphorylation was significantly reduced in GO cells (�p<0.05) (Fig 6A); Akt and JNK
phosphorylation was inhibited in non-GO cells (�p<0.05) (Fig 6B).
Discussion
In this study, we investigated the role of PTP1B in the pathogenesis of GO and evaluated
whether suppression of PTP1B could reverse inflammation, oxidative stress, and fibrosis in
GO cells. PTPN1 silencing significantly inhibited proinflammatory cytokine production, ROS
generation induced by H2O2 or CSE, and the expression of proteins related to TGF-β-induced
Fig 3. Effect of PTP1B suppression on CSE- or H2O2-induced intracellular ROS generation. GO cells were
transfected with sicontrol or siPTPN1 for 24 hours. Cells were pretreated with H2DCFDA for 30 minutes in all GO
fibroblast groups. Then, cells were exposed to 2% CSE or 200 μM H2O2 for 30 minutes. Experiments were performed
using three cells from different individual samples. (A) Intracellular ROS generation was quantified by flow-cytometry
with H2DCFDA. The bar graphs show mean ratios ± SD relative to the sicontrol without CSE or H2O2 treatment.
(�p<0.05, sicontrol versus siPTPN1) (B) ROS production was observed using an inverted fluorescence microscope at
40x magnifications.
https://doi.org/10.1371/journal.pone.0237015.g003
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fibrosis in GO cells. Furthermore, PTPN1 silencing resulted in the amelioration of ER stress
and suppression of the phosphorylation of Akt, p38, and JNK signalling pathway molecules
without affecting cell viability. Protein tyrosine phosphorylation is regulated through coordi-
nation between protein tyrosine kinases and phosphatases; disturbance of the balance between
the two enzymes results in aberrant tyrosine phosphorylation, which is implicated in several
human diseases, including cancer, diabetes, and inflammation [26]. This study is, to our
knowledge, the first to find that PTP1B suppression has a protective effect in vitro against GO
pathologic mechanisms.
Recently, bidirectional crosstalk between TSHR and IGF-1R was demonstrated in GO
fibroblasts. Here, we evaluated whether PTP1B was stimulated by M22, bTSH, IGF-1, IL-1β,
or TNF-α in GO fibroblasts. There have been no previous studies linking TSHR and PTP1B
signalling. In this study, we demonstrated that the treatment of orbital fibroblasts with TSHR
or IGFR ligands upregulated the expression of PTP1B in both GO and non-GO cultures,
although the mechanism is still unclear. IGF-1 activity is reported to be negatively controlled
by the action of PTP1B [27] and inhibiting PTP1B is considered to have neuroprotective
effects in diabetic retinopathy by modulating IGF-1 activity [28]. Proinflammatory cytokines
have previously been shown to increase PTP1B levels, similar to our findings in orbital fibro-
blasts. TNF-α treatment increased PTP1B levels by 2- to 5-fold in adipocytes and hepatocytes;
moreover, administration of TNF-α to mice resulted in elevated PTP1B mRNA levels in the
adipose tissue, skeletal muscle, hypothalamic arcuate nucleus, and liver [29].
Fig 4. Effect of PTP1B suppression on the fibrosis of orbital fibroblasts. Orbital fibroblasts from GO and non-GO patients transfected with sicontrol
or siPTPN1 for 24 hours were exposed to TGF-β (5 ng/mL) for 24 hours. Cell lysates of GO fibroblasts (A) and non-GO fibroblasts (B) were subjected
to western blot analysis of fibronectin, collagen Iα, and α-SMA protein expression. Experiments were performed in three GO cell strains and non-GO
cell strains taken from different individuals. Data in the columns indicate the mean density ratio ± SD by densitometry normalised to the level of β-
actin in the same sample. Representative gel images are shown. Differences between sicontrol and siPTPN1 are indicated (�p<0.05). See S3 Fig for
uncropped blots.
https://doi.org/10.1371/journal.pone.0237015.g004
PLOS ONE PTP1B as a therapeutic target for GO
PLOS ONE | https://doi.org/10.1371/journal.pone.0237015 August 6, 2020 9 / 16
Fig 5. Role of PTP1B suppression on ER stress. GO fibroblasts were transfected with sicontrol or siPTPN1 for 24
hours and exposed to IL-1β (10 ng/mL) for 1 hour or 48 hours. The GO fibroblasts were lysed and proteins related ER
stress such as BiP, CHOP, ATF4, ATF6α, phosphorylated and total eIF2α, IRE1α, and PERK were analysed by western
blot. Experiments were performed in three GO cells from different individuals. (A) Representative gel images are
shown. (B,C) Data in the columns represent the mean density ratio ± SD by densitometry normalised to the level of β-
actin in the same sample for 1 hour and 48 hours, respectively. Differences between sicontrol and siPTPN1 are
indicated (�p<0.05). See S3 Fig for uncropped blots.
https://doi.org/10.1371/journal.pone.0237015.g005
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Orbital inflammation progresses by the infiltration of mononuclear cells, such as B-lym-
phocytes, macrophages, and especially T-lymphocytes, into the orbital tissue in GO [30, 31].
Furthermore, as previously reported [32], GO fibroblast was more inflammatory by nature
and were sensitive to stimulation. Herein, compared to non-GO cells, GO fibroblasts dis-
played increased secretion of pro-inflammatory cytokines upon IL-1β stimulation and even
in naïve conditions. PTPN1 silencing in GO cells reduced proinflammatory proteins, includ-
ing IL-6, IL-8, MCP-1, Cox-2, ICAM1, and p-NF-κB. However, in non-GO fibroblasts,
proinflammatory proteins except for Cox-2 were not significantly curtailed upon PTP1B
suppression. PTP1B seems to play a specific role in GO cells, which serves as a positive regu-
lator of inflammation.
There are still controversies regarding the role of PTP1B in the inflammatory mechanism.
It has been shown that PTP1B plays a key role in converting dendritic cells to an active and
Fig 6. Effect of PTP1B suppression on signalling pathways in orbital fibroblasts. GO and non-GO cells were transfected with sicontrol or siPTPN1
for 24 hours and then exposed to IL-1β (10 ng/mL) for 1 hour. Phosphorylated and total Akt, ERK, p38, and JNK were determined by western blotting
in GO fibroblasts (A) and non-GO fibroblasts (B). Experiments were performed in three GO and non-GO cells from different individuals.
Representative bands are shown. Data in the columns indicate the mean density ratio ± SD by densitometry normalised to the level of β-actin in the
same sample. Differences between sicontrol and siPTPN1 are indicated (�p<0.05). See S3 Fig for uncropped blots.
https://doi.org/10.1371/journal.pone.0237015.g006
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mature state and activating T cells by displaying podosomes [33]. In PTP1B-deficient mice
with induced colitis, inflammation was suppressed by the production of myeloid-derived sup-
pressor cells, which have characteristic T cell-suppressant functions [34]. PTP1B blockage in
microglial cells inhibited the production of lipopolysaccharide-induced proinflammatory mol-
ecules, such as IL-1β, TNF-α, Cox-2, and iNOS [35], and protected microglial cells against
hypothalamic inflammation by activating the JAK2-STAT3 signalling pathway [36]. In con-
trast, there are several opposing reports insisting that PTP1B is a negative regulator of inflam-
mation. PTP1B knockout in the spleen leukocytes of mice resulted in increased chemotaxis
and transendothelial migration and exacerbated allergic inflammation [37]. Acute pancreatitis
was enhanced in PTP1B knockout mice via increased production of inflammatory cytokines,
such as IL-1β, IL-6, and TNF-α [38]. PTP1B is ubiquitously expressed and performs different
functions in various tissues. Therefore, modulation of PTP1B has different results depending
on the cell type in vitro as well as the specific tissue in vivo [6, 11].
PTP1B has been reported to promote fibrosis in many other cell types. Genetic deletion of
PTP1B and administration of PTP1B inhibitors reduced cardiac fibrosis in chronic heart fail-
ure mice [39]. In the endothelial cell-specific PTP1B KO mouse, cardiac fibrosis was reduced
via elevation in caveolin-1, which inhibited ROS generation and suppressed TGF-β signalling
[40]. In addition, PTP1B plays a regulatory role in liver fibrosis. PTP1B blocking using siRNA
inhibited the proliferation and activation of hepatic stellate cells induced by TGF-β1 [41].
PTP1B-depleted hepatocytes showed resistance to TGF-β through the activation of NADPH
oxidase 1 [42]; moreover, hepatic fibrosis in response to cholestatic liver injury was amelio-
rated by the same mechanism [43]. In our study on GO orbital fibroblasts, PTPN1 silencing
down-regulated all fibrosis-related proteins induced by TGF-β, which was not evident in non-
GO fibroblasts.
Systemic hyperthyroidism and T cell infiltration into orbital tissue leads to ROS production,
and oxidative stress from cigarette smoking can aggravate GO severity by increasing T cell pro-
liferation, adipogenesis, and glycosaminoglycan production in orbital fibroblasts [44–46]. Our
study shows that PTPN1 silencing ameliorated ROS generation in both CSE- and H2O2-stimu-
lated cells. Regarding oxidative stress, PTP1B deficiency in skeletal muscle cells resulted in the
reduction of ceramide and ROS levels, whereas overexpression of PTP1B showed the opposite
effect [47]. PTP1B deletion reduced mitochondrial dysfunction by increasing the expression of
SIRT1 and reducing the phosphorylation of p65. PTP1B inhibition in mouse hepatocytes ame-
liorated acetaminophen-induced cell death and reduced GSH depletion, ROS generation, and
activation of JNK and p38. PTP1B inhibition also enhanced the expression of the Nrf2-target
gene heme oxygenase-1 (HO-1), suggesting that PTP1B plays a key regulatory role in the anti-
oxidant system [48].
The changes in the phosphorylation level of multiple transcription factors following PTP1B
inhibition in GO fibroblasts indicate that a more complex network of signalling pathways may
exist. Kumar et al. discovered that an autoantibody to TSHR stimulated the PI3K/Akt pathway
downstream and induced adipogenesis in orbital preadipocytes in GO [22]. Herein, PTP1B
inhibition suppressed IL-1β-induced Akt, JNK phosphorylation in GO and non-GO fibro-
blasts. However, p38 MAPK phosphorylation was reduced by PTP1B inhibition only in GO
fibroblasts. The p38 and JNK pathways, along with the MAPK pathway, are well-known for
mediating the transcription and translation of inflammatory cytokines; moreover, they have
been considered as targets of anti-inflammatory therapy [24, 25]. In several other disease-spe-
cific cell models, JNK and p38 phosphorylation was ameliorated by PTP1B inhibition [47, 48].
The downregulation of inflammation and its associated transcription factors with siPTPN1
may be related to a blocked ER stress response. It has been well-documented that the ER stress
response, also known as the unfolded protein response (UPR), activates inflammation by
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inducing the NF-κB and JNK pathways [49, 50]. The upregulation of UPR molecules in autoim-
mune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory
bowel syndrome, has shown this relationship [50, 51]. PTP1B is located in the cytoplasmic
region of the ER and plays an active role in the UPR. Gu et al. reported that PTP1B KO embry-
onic fibroblasts showed reduced IRE1 signalling, specific XBP-1 splicing, and JNK pathway
activation; moreover, they were resistant to ER stress-induced apoptosis [52]. Similarly, liver-
specific PTP1B deletion impaired the UPR by suppressing the phosphorylation of UPR mole-
cules such as PERK, eIF2α, p38, JNK, and CHOP under a high fat-induced ER stress environ-
ment [53, 54]. Additionally, mouse myoblasts transfected with PTP1B siRNA exhibited
attenuated phosphorylation of eIF2α and JNK1/2 [55]. Our results demonstrated that PTPN1
silencing blocks part of the UPR cascade by reducing the expression of proteins such as BiP,
eIF2α, IRE1α, and CHOP. However, PTPN1 silencing did not affect apoptosis and cell viability.
To our knowledge, this study demonstrates for the first time that PTP1B mediates inflam-
matory reactions in GO fibroblasts. We found that PTPN1 silencing attenuated inflammation,
fibrosis, and ROS generation, which could possibly be associated with the suppression of the
ER stress response pathway and Akt, JNK, and p38 phosphorylation in GO cells. Inhibiting
PTP1B might be a novel therapeutic option for the treatment of GO related to inflammatory
and oxidative stressors. In addition, the inhibitory effect of PTP1B modulation on TGF-β
induced fibrosis could also contribute to controlling fibrotic events in GO. Further studies are
necessary to prove the in vivo effect of PTP1B inhibition in GO in clinically applications.
Supporting information
S1 Fig. TLR expressions depending on PTPN1 silencing in orbital fibroblasts. GO and non-
GO fibroblasts were transfected with sicontrol or siPTPN1 for 24hours. TLR2, 4, and 9 expres-
sion levels were quantified with RT-PCR. Data in the columns indicate relative TLR mRNA
fold of siPTPN1 cells normalised to sicontrol of each cell type (�p<0.05, sicontrol versus
siPTPN1). Experiments were performed in three GO and non-GO fibroblasts from different
individuals.
(TIF)
S2 Fig. Effect of PTP1B blocking on cell viability and apoptosis. Orbital fibroblasts from
GO and non-GO patients were transfected with sicontrol and siPTPN1 for 24 hours. (A) After
the transfection, cells were cultured in different conditions (with or without IL-1β) for 24
hours and 48 hours. Then, the viability of the cells was assessed with MTT assay. Difference
between sicontrol and sicontrol with IL-1β stimulation in GO was indicated (�p<0.05). (B)
The transfected cells were subjected to Annexin V apoptosis assay after incubating for 24
hours and 48 hours. Assays were performed using three GO and non-GO cells from different
individuals.
(TIF)
S3 Fig. Uncropped version of western blots.
(TIF)
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